Monitor Phase 2 initiation for ATTO-1310 in CPUO and high-itch AD expected H1 2027, and Phase 1 starts for ATTO-2306 and ATTO-1091. Full Phase 1b data for ATTO-1310 expected Q4 2026/Q1 2027. The IPO provides sufficient capital to reach key catalysts, but clinical execution risk remains high.
Executive Summary
Attovia Therapeutics filed Amendment No. 2 to its S-1 for an IPO of 17,000,000 shares at an estimated $17.00 per share, targeting ~$265M in net proceeds. The clinical-stage biopharma is advancing three ATTOBODY-based candidates for immune-mediated diseases, with lead candidate ATTO-1310 showing promising Phase 1b itch relief data. Proceeds will fund Phase 2 trials for ATTO-1310 and ATTO-2306, plus early development of ATTO-1091, extending cash runway into 2029.
Key Financial Metrics
Key Facts
- IPO of 17,000,000 shares at $17.00/share; estimated net proceeds of $265.1M ($305.4M with over-allotment)
- Cash, cash equivalents and marketable securities of $132.6M as of March 31, 2026; preliminary $115.1M as of June 30, 2026
- Net losses of $60.6M in FY2025 and $18.7M in Q1 2026; accumulated deficit of $129.7M
- Lead candidate ATTO-1310 (anti-IL-31) completed Phase 1 dosing; Phase 1b data showed 65% of chronic pruritus patients achieved ≥4-point itch reduction at week 4
- Pipeline includes ATTO-2306 (IL-13/IL-31 bispecific) and ATTO-1091 (TL1A/IL-23/integrin α4β7 trispecific), both in IND-enabling studies
- Use of proceeds: $110-130M for ATTO-1310 Phase 2, $60-80M for ATTO-2306 Phase 2, remainder for pipeline and working capital
Financial Impact
IPO raises ~$265M net, increasing pro forma cash to ~$399M, funding operations into 2029. No product revenue; collaboration revenue of $1.35M in FY2025.
Risk Factors
- Clinical trial failure or delays for all three pipeline candidates
- Need for substantial additional capital beyond IPO to complete development and commercialization
- Intense competition from approved therapies (Dupixent, Nemluvio, EBGLYSS) and other developers
- Dependence on third-party manufacturers (including WuXi) and CROs
- Early stage with no approved products or product revenue
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001193125-26-331510 |
| Document: d40469dexfilingfees.htm | 0001193125-26-331510 |
| Document: d40469dex51.htm | 0001193125-26-331510 |
| Document: d40469dex231.htm | 0001193125-26-331510 |
| Document: 0001193125-26-331510-index-headers.html | 0001193125-26-331510 |
| Document: 0001193125-26-331510-index.html | 0001193125-26-331510 |
| Document: 0001193125-26-331510.txt | 0001193125-26-331510 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Oct 8, 2026 19d ago | 3/A | $16.21 | awaiting T+20 | — | $13.88 (−14.37%) |
Sep 28, 2026 29d ago | Press Release | $18.16 $15.00 | ▼ −17.40% | ▼ −18.12% | $13.88 (−23.57%) |
Sep 2, 2026 7w ago | Press Release | $24.20 $17.14 | ▼ −29.17% | ▼ −28.06% | $13.88 (−42.64%) |
Aug 28, 2026 8w ago | 144 / CLUSTER | $21.40 $18.16 | ▼ −15.14% | ▼ −14.95% | $13.88 (−35.14%) |
Aug 13, 2026 10w ago | Insider Buy | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 13, 2026 10w ago | Insider Cluster | $19.86 $24.52 | ▲ +23.46% | ▲ +25.46% | $13.88 (−30.11%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.65 $22.86 | ▲ +22.57% | ▲ +23.63% | $13.88 (−25.58%) |
Aug 7, 2026 11w ago | Insider Cluster | $19.84 $23.66 | ▲ +19.25% | ▲ +20.17% | $13.88 (−30.04%) |
Aug 7, 2026 11w ago | Insider Cluster | $20.17 $25.55 | ▲ +26.67% | ▲ +27.07% | $13.88 (−31.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers